Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Protalix BioTherapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +2 vs. Q4 2021
- Shares held
- 1.22M
- −1.71M (−58.3%) vs. Q4 2021
- Total value
- $1.29M
- −$1.15M (−47.1%) vs. Q4 2021
- New holders
- 9
- 5 more added
- Sold out
- 7
- 9 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PLX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 101 | $33.7M |
| Q1 2026 | 100 | $36.6M |
| Q4 2025 | 83 | $26.8M |
| Q3 2025 | 77 | $30.9M |
| Q2 2025 | 63 | $17.6M |
| Q1 2025 | 63 | $21.0M |
| Q4 2024 | 46 | $8.40M |
| Q3 2024 | 45 | $3.53M |
| Q2 2024 | 66 | $6.60M |
| Q1 2024 | 64 | $11.9M |
| Q4 2023 | 66 | $17.6M |
| Q3 2023 | 61 | $15.2M |
| Q2 2023 | 66 | $17.9M |
| Q1 2023 | 34 | $6.15M |
| Q4 2022 | 26 | $4.87M |
| Q3 2022 | 27 | $3.70M |
| Q2 2022 | 30 | $1.30M |
| Q1 2022 | 32 | $1.29M |
| Q4 2021 | 31 | $2.45M |
| Q3 2021 | 35 | $5.91M |
| Q2 2021 | 33 | $8.24M |
| Q1 2021 | 38 | $39.4M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Protalix BioTherapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 15 | $0 | 0.00% | −485−97.0% | Reduced |
| UBS Group AG | 120 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 300 | $0 | 0.00% | +300 | New |
| American Portfolios Advisors | 500 | $530 | 0.00% | +500 | New |
| Captrust Financial Advisors | 800 | $1.00K | 0.00% | 00.0% | Unchanged |
| Ten Capital Wealth Advisors, LLC | 790 | $1.00K | 0.00% | +140+21.5% | Added |
| JPMorgan Chase & Co | 1,127 | $1.00K | 0.00% | +1,127 | New |
| Federation des caisses Desjardins du Quebec | 1,100 | $1.17K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 2,000 | $2.00K | 0.00% | +2,000 | New |
| Bank of America Corp | 5,153 | $5.00K | 0.00% | −12,234−70.4% | Reduced |
| National Bank of Canada | 6,100 | $6.00K | 0.00% | +100+1.7% | Added |
| Federated Hermes, Inc. | 5,761 | $6.00K | 0.00% | 00.0% | Unchanged |
| Psagot Value Holdings Ltd. / (Israel) | 6,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| TD Waterhouse Canada Inc. | 6,000 | $6.24K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,465 | $7.00K | 0.00% | +6,393+8,879.2% | Added |
| Aptus Capital Advisors, LLC | 11,451 | $12.0K | 0.00% | +11,451 | New |
| Susquehanna International Group, LLP | 12,119 | $13.0K | 0.00% | −69,831−85.2% | Reduced |
| Davenport & Co LLC | 12,000 | $13.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 11,900 | $13.0K | 0.00% | +11,900 | New |
| Smith, Salley & Associates | 12,048 | $13.0K | 0.00% | +12,048 | New |
| Virtu Financial LLC | 15,199 | $16.0K | 0.00% | −3,172−17.3% | Reduced |
| Morgan Stanley | 23,917 | $25.0K | 0.00% | −1,269,046−98.2% | Reduced |
| IHT Wealth Management, LLC | 24,000 | $25.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 28,790 | $31.0K | 0.00% | +28,790 | New |
| Group One Trading, L.P. | 32,646 | $35.0K | 0.00% | −597,900−94.8% | Reduced |
| Susquehanna Fundamental Investments, LLC | 41,574 | $44.0K | 0.00% | −1,326−3.1% | Reduced |
| Two Sigma Advisers, LP | 58,900 | $62.0K | 0.00% | −41,000−41.0% | Reduced |
| BlackRock Inc. | 109,061 | $116.0K | 0.00% | −5,337−4.7% | Reduced |
| Jane Street Group, LLC | 145,208 | $154.0K | 0.00% | +59,550+69.5% | Added |
| Spire Wealth Management | 148,800 | $158.0K | 0.00% | +23,000+18.3% | Added |
| Meitav Dash Investments Ltd | 244,332 | $257.0K | 0.00% | +244,332 | New |
| Phoenix Holdings Ltd. | 244,113 | $259.0K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −40,290−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −29,015−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −24,527−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −10,067−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −2,432−100.0% | Sold out |
| Rinkey Investments | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Snowden Capital Advisors LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Finivi Inc. | – | – | – | – | Not filed |